09/16/2026
AI is already finding its way into pharmaceutical quality systems. The more important question is whether the controls around it have caught up.
In April 2026, the FDA issued a warning letter that explicitly addressed inappropriate use of artificial intelligence in pharmaceutical manufacturing. But the implications extend well beyond one enforcement action.
Our upcoming webinar, **AI in the Quality Unit: What FDA’s First AI Warning Letter Didn’t Tell You**, looks at where AI-generated content can quietly enter controlled processes, how those risks differ depending on the way AI is being used, and how existing quality systems can be adapted to govern it.
For professionals across QA, QC, Regulatory Affairs, CMC and validation, this is an opportunity to move the AI conversation away from abstraction and into the realities of documentation, attribution, training, validation and regulatory oversight.
And for this session, we’re opening the conversation a little wider. Use SAVE99 at registration to quietly take the $99 cost out of the equation. Visit aapspharma.com/events to register